Cardiac Myosin Inhibition for Treatment of LVOT Obstruction in a Patient With Severe AS

Area of Science:

• Cardiology
• Cardiac Surgery
• Pharmacology

Background:

• Aortic stenosis and obstructive hypertrophic cardiomyopathy are common cardiovascular conditions.
• Managing patients with both conditions presents significant clinical challenges.
• Current treatment strategies require careful consideration of overlapping pathologies.

Observation:

• This case report details the management of a patient with concomitant AS and oHCM.
• The patient received a cardiac myosin inhibitor prior to intervention.
• Transcatheter aortic valve replacement (TAVR) was subsequently performed.

Findings:

• The study reports the first documented instance of utilizing a cardiac myosin inhibitor pre-TAVR in a patient with AS and oHCM.
• This approach may offer a novel therapeutic pathway for managing obstructive physiology in this patient population.

Implications:

• This pioneering use suggests a potential role for cardiac myosin inhibitors in optimizing patients for TAVR when oHCM is present.
• Further research is warranted to explore the safety and efficacy of this combined therapeutic strategy.
• This approach could improve outcomes for patients with complex cardiovascular comorbidities.